EA199900427A1 - Способ кристаллизации лозартана - Google Patents

Способ кристаллизации лозартана

Info

Publication number
EA199900427A1
EA199900427A1 EA199900427A EA199900427A EA199900427A1 EA 199900427 A1 EA199900427 A1 EA 199900427A1 EA 199900427 A EA199900427 A EA 199900427A EA 199900427 A EA199900427 A EA 199900427A EA 199900427 A1 EA199900427 A1 EA 199900427A1
Authority
EA
Eurasian Patent Office
Prior art keywords
losartan
potassium
crystallization method
bulk
angiotensin
Prior art date
Application number
EA199900427A
Other languages
English (en)
Other versions
EA001046B1 (ru
Inventor
Патрик Брин
Эрик А. Дайенманн
Альберт Д. Эпштейн
Карен А. Ларсон
Майкл Т. Кеннеди
Хари Махадеван
Original Assignee
Мерк Энд Ко., Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9625804.1A external-priority patent/GB9625804D0/en
Application filed by Мерк Энд Ко., Инк. filed Critical Мерк Энд Ко., Инк.
Publication of EA199900427A1 publication Critical patent/EA199900427A1/ru
Publication of EA001046B1 publication Critical patent/EA001046B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)

Abstract

Калий-лозартан является антагонистом ангиотензина II, пригодным для лечения гипертензии и застойной сердечной недостаточности (I). Настоящее изобретение относится к способу управляемой кристаллизации калий-лозартана с использованием добавления антирастворителя в сочетании с массовым внесением затравок с целью получения желаемой морфологии кристалла и объемных физических свойств, необходимых для успешного приготовления лекарственных препаратов.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA199900427A 1996-10-29 1997-10-24 Способ кристаллизации лозартана EA001046B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2932696P 1996-10-29 1996-10-29
GBGB9625804.1A GB9625804D0 (en) 1996-12-12 1996-12-12 Process for the crystallization of losartan
PCT/US1997/019442 WO1998018787A1 (en) 1996-10-29 1997-10-24 Process for the crystallization of losartan

Publications (2)

Publication Number Publication Date
EA199900427A1 true EA199900427A1 (ru) 1999-10-28
EA001046B1 EA001046B1 (ru) 2000-08-28

Family

ID=26310606

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199900427A EA001046B1 (ru) 1996-10-29 1997-10-24 Способ кристаллизации лозартана

Country Status (18)

Country Link
US (1) US5859258A (ru)
EP (1) EP0937068B1 (ru)
JP (1) JP3249827B2 (ru)
CN (1) CN1101393C (ru)
AR (1) AR010256A1 (ru)
AT (1) ATE214388T1 (ru)
AU (1) AU5089898A (ru)
BR (1) BR9712390A (ru)
CZ (1) CZ291672B6 (ru)
DE (1) DE69711068T2 (ru)
DK (1) DK0937068T3 (ru)
EA (1) EA001046B1 (ru)
ES (1) ES2173433T3 (ru)
HR (1) HRP970565B1 (ru)
PT (1) PT937068E (ru)
SK (1) SK282875B6 (ru)
TW (1) TW411338B (ru)
WO (1) WO1998018787A1 (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001226372A (ja) * 1999-12-06 2001-08-21 Sumika Fine Chemicals Co Ltd ロサルタンの結晶性または結晶化された酸付加塩およびロサルタンの精製方法
JP2002080354A (ja) * 2000-09-05 2002-03-19 Kao Corp 血圧降下剤組成物
BR0102252B1 (pt) * 2001-04-10 2013-10-22 Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso
EP1294712A1 (en) * 2001-05-18 2003-03-26 Aurobindo Pharma Limited Process for the crystallization of losartan potassium
US7429238B2 (en) * 2001-10-15 2008-09-30 The Regents Of The University Of Michigan Systems and methods for the generation of crystalline polymorphs
US7413751B2 (en) * 2001-10-25 2008-08-19 Depomed, Inc. Methods of treatment using a gastric retained losartan dosage
EP1634880A3 (en) 2002-04-29 2006-04-12 Teva Pharmaceutical Industries Ltd. Processes for preparing losartan and losartan potassium
US20040097568A1 (en) * 2002-07-29 2004-05-20 Dr. Reddy's Laboratories Limited Crystalline form of losartan potassium
US20040171843A1 (en) * 2002-10-17 2004-09-02 Igor Lifshitz Process for preparing losartan potassium with improved flow ability
AU2003278422A1 (en) * 2002-10-31 2004-05-25 Ranbaxy Laboratories Limited Amorphous form of losartan potassium
US7271269B2 (en) * 2003-01-30 2007-09-18 Lek Pharmaceuticals D.D. Preparation of new pharmaceutically suitable salt of losartan and forms thereof with new purification and isolation methods
WO2004076442A1 (en) * 2003-02-28 2004-09-10 Ranbaxy Laboratories Limited Polymorphs of losartan
US7345071B2 (en) 2003-05-07 2008-03-18 Ipca Laboratories Limited Process for the synthesis of Losartan potassium
ITMI20032472A1 (it) * 2003-12-16 2005-06-17 Dinamite Dipharma S P A In Forma A Bbreviata Diph Procedimento per la preparazione di losartan potassio cristallino
EP1709034A2 (en) * 2004-01-06 2006-10-11 IPCA Laboratories Limited An improved process for the synthesis of losartan potassium
US20050288272A1 (en) * 2004-06-23 2005-12-29 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists
CN1972679B (zh) * 2004-06-23 2010-07-28 索尔瓦药物有限公司 包括nep-抑制剂、内源性内皮缩血管肽产生系统抑制剂和at1受体拮抗剂的药物组合物
ITMI20050551A1 (it) * 2005-04-01 2006-10-02 Dipharma Spa Forma cristallina alfa di losartan potassio
CA2668744C (en) 2006-11-17 2015-09-15 Queen's University At Kingston Compounds and methods for treating protein folding disorders
ES2315141B1 (es) * 2006-11-23 2009-12-22 Quimica Sintetica, S.A Procedimiento para la preparacion de cardesartan cilexetilo en forma cristalina.
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
DE69233734D1 (de) * 1991-11-18 2008-06-26 Du Pont 2-(2'-Triphenylmethyl-2'H-tetrazol-5'-yl)phenylborsäure als Zwischenprodukt zur Synthese von A II Receptorenantagonisten
US5310928A (en) * 1991-11-18 1994-05-10 E. I. Du Pont De Nemours And Company Process for preparing biphenyltetrazole compounds
US5206374A (en) * 1991-11-18 1993-04-27 E. I. Du Pont De Nemours And Company Process for preparing tetrazolylphenylboronic acid intermediates
US5130439A (en) * 1991-11-18 1992-07-14 Lo Young S Tetrazolylphenylboronic acid intermediates for the synthesis of AII receptor antagonists
EP0736021A4 (en) * 1993-12-23 1997-04-02 Merck & Co Inc LOSARTANE POLYMORPHS AND PROCESS FOR THE PREPARATION OF FORM II OF LOSARTANE

Also Published As

Publication number Publication date
AR010256A1 (es) 2000-06-07
ES2173433T3 (es) 2002-10-16
JP2000504343A (ja) 2000-04-11
US5859258A (en) 1999-01-12
AU5089898A (en) 1998-05-22
EP0937068A1 (en) 1999-08-25
DE69711068T2 (de) 2002-09-12
CN1241186A (zh) 2000-01-12
CN1101393C (zh) 2003-02-12
CZ151599A3 (cs) 1999-10-13
HRP970565B1 (en) 2003-02-28
BR9712390A (pt) 1999-08-31
CZ291672B6 (cs) 2003-04-16
JP3249827B2 (ja) 2002-01-21
SK57099A3 (en) 2000-02-14
HRP970565A2 (en) 1998-08-31
TW411338B (en) 2000-11-11
EA001046B1 (ru) 2000-08-28
DK0937068T3 (da) 2002-05-21
WO1998018787A1 (en) 1998-05-07
ATE214388T1 (de) 2002-03-15
PT937068E (pt) 2002-07-31
SK282875B6 (sk) 2003-01-09
DE69711068D1 (de) 2002-04-18
EP0937068B1 (en) 2002-03-13

Similar Documents

Publication Publication Date Title
EA199900427A1 (ru) Способ кристаллизации лозартана
ES2062403T3 (es) 5-((tetrazolil)-alquenil)-imidazoles sustituidos.
MY110205A (en) Imidazolyl-alkenoic acids.
PT85312A (en) Process for the preparation of angiotension ii receptor blocking imidazoles and of pharmaceutical
ATE250587T1 (de) Imidazoalkensäure
EA200300671A1 (ru) Производные хиназолина, содержащие эти соединения лекарственные средства, их применение и способ их получения
ES2060951T5 (es) Azaindenos.
ATE92478T1 (de) Substituierte pyrrol-, pyrazol- und triazolangiotensin ii-antagonisten.
EA200100955A1 (ru) 4-ОКСО-4,7-ДИГИДРОТИЕНО [2,3-b]ПИРИДИН-5-КАРБОКСАМИДЫ В КАЧЕСТВЕ АНТИВИРУСНЫХ СРЕДСТВ
EA199900045A1 (ru) Производные спиропиперидина и их использование в качестве терапевтических агентов
ATE259243T1 (de) Fettleibigkeitsprotein (ob) zur erhögung der mageren körpermasse
ATE119524T1 (de) Substituierte n-(imidazolyl)alkyl-alanin- derivate.
EA200000057A1 (ru) (+)-норцисаприд, пригодный для лечения нарушений, опосредованных 5-нт3 и 5-нт4 (рецепторами)
DE69431534D1 (de) Bindegewebswachstumsfaktor-2
WO1992020651A3 (en) N-(heteroaryl)-imidazolyl-alkenoic acids
EA200200562A1 (ru) Антагонисты аденозиновых рецепторов и способы их получения и использования
EA199700242A1 (ru) Индазолкарбоксамиды, способ их получения, фармкомпозиция и способ ингибирования 5-нтрецептора
ATE237611T1 (de) Cyclische harnstoff- und lactamderivate von benzo(5,6)cycloheptapyridinen zur verwendung als farnesyl-protein-transferase-hemmer
EE03046B1 (et) Angiotensiin II retseptorite antagonistide triasolopürimidiinide derivaadid, nende valmistamise meetod ja ravimvormid
SU1440490A1 (ru) Способ лечени привычного вывиха плеча
CA1272214C (ru)
ATE252902T1 (de) Verwendung von calciumkanalanantagonisten zur behandlung von herz-, nieren-, magen-und darmkrankheiten sowie bluthochdruck
SU1637784A1 (ru) Способ лечени деформаций перегородки носа
EA200100107A1 (ru) Новые 2,3,3a,4,9,9a-гексагидро-8-гидрокси-1h-бенз[f]индолы, способ их получения и их применение в качестве лекарственных средств
RU93057110A (ru) Способ аппендэктомии

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU